Developing a Vaccine Against Multiple Psychoactive Targets: A Case Study of Heroin

Author(s): G. Neil Stowe, Joel E. Schlosburg, Leandro F. Vendruscolo, Scott Edwards, Kaushik K. Misra, Gery Schulteis, Joseph S. Zakhari, George F. Koob, Kim D. Janda

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 10 , Issue 8 , 2011

Become EABM
Become Reviewer


Heroin addiction is a wide-reaching problem with a spectrum of damaging social consequences. Currently approved heroin addiction medications include drugs that bind at the same receptors (e.g. opioid receptors) occupied by heroin and/or its metabolites in the brain, but undesired side effects of these treatments, maintenance dependence and relapse to drug taking remains problematic. A vaccine capable of blocking heroin's effects could provide an economical, long-lasting and sustainable adjunct to heroin addiction therapy without the side effects associated with available treatment options. Heroin, however, presents a particularly challenging vaccine target as it is metabolized to multiple psychoactive molecules of differing lipophilicity, with differing abilities to cross the blood brain barrier. In this review, we discuss the opiate scaffolding and hapten design considerations to confer immunogenicity as well as the specificity of the immune response towards structurally similar opiates. In addition, we detail different strategies employed in the design of immunoconjugates for a vaccine-based therapy for heroin addiction treatment.

Keywords: Heroin, 6-acety-morphine, morphine, addiction, drug dependence, immunoconjugate, treatment, therapy, HIV, AChE, Blood Brain Barrier, Rehabilitation Therapy, Keyhole Limpet Hemocyanin, ELISA

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [865 - 875]
Pages: 11
DOI: 10.2174/187152711799219316
Price: $65

Article Metrics

PDF: 10